Tag: antibody-drug conjugate

A case report describes a durable 54.5 percent shrinkage of a dural-based brain metastasis in a patient with HER2-negative salivary ...

A large single-center analysis finds that metastatic metaplastic triple-negative breast cancer responds less well to sacituzumab govitecan than typical triple-negative ...

A large real-world analysis of TriNetX health records finds that mirvetuximab soravtansine carries elevated risks of corneal toxicity and peripheral ...

A prospective Chinese pediatric study found that brentuximab vedotin combined with risk-adapted chemoimmunotherapy achieved 100 percent overall survival and allowed ...

The Phase 3 EVOKE-03/KEYNOTE-D46 trial found that sacituzumab govitecan plus pembrolizumab did not significantly improve progression-free or overall survival compared ...

First clinical data from the Phase 1b/2 BNT324-01 trial show that the investigational combination of pumitamig and elfetabart drozuntecan achieved ...

An investigational EGFR x HER3 antibody-drug conjugate showed promising efficacy and a manageable safety profile in previously treated EGFR-mutated lung ...

In a finding that could reshape the treatment landscape for one of the most difficult scenarios in breast cancer care, ...

In a groundbreaking multi-center, real-world study recently published in BMC Cancer, researchers unveil critical insights into the clinical efficacy of ...

In a landmark development in the treatment of relapsed small cell lung cancer (SCLC), scientists have unveiled promising results from ...